

Targeted disruption of the mouse phospholipase C β_3 gene results in early embryonic lethality

Shu Wang^a, Samuel Gebre-Medhin^b, Christer Betsholtz^b, Peter Stålberg^a, Yinghua Zhou^a, Catharina Larsson^c, Gunther Weber^c, Ricardo Feinstein^d, Kjell Öberg^a, Anders Gobl^a, Britt Skogseid^{a,*}

^aDepartment of Internal Medicine, University Hospital, 751 85 Uppsala, Sweden

^bDepartment of Medical Biochemistry, University of Gothenburg, 413 90 Gothenburg, Sweden

^cDepartment of Clinical Genetics, Karolinska Hospital, 104 01 Stockholm, Sweden

^dDepartment of Pathology, The National Veterinary Institute, 750 07 Uppsala, Sweden

Received 13 September 1998; received in revised form 19 October 1998

Abstract In order to investigate the biological function of phosphatidylinositol-specific phospholipase C (PLC) we generated mutant mice by gene targeting. Homozygous inactivation of PLC β_3 is lethal at embryonic day 2.5. These mutants show poor embryonic organization as well as reduced numbers of cells. Identical phenotypes were recorded in homozygous mutants generated from two independently targeted embryonic stem cell clones. Heterozygous mutant mice, however, are viable and fertile for at least two generations. We also showed that mouse PLC β_3 is expressed in unfertilized eggs, 3-cell and egg cylinder stages of embryos. In conclusion, these results indicate that PLC β_3 expression is essential for early mouse embryonic development.

© 1998 Federation of European Biochemical Societies.

Key words: Phospholipase C β_3 ; Signal transduction; Targeted disruption; Early embryonic development; Preimplantational lethality

1. Introduction

Phosphatidylinositol-specific phospholipase C (PLC) is implicated to be activated in the mammalian oocyte at fertilization [1]. Preincubation of mouse eggs with the PLC inhibitor, U73122, greatly reduces their Ca²⁺ responsiveness to acetylcholine as well as spermatozoa activation [2]. Blastocoele formation in the mouse is also inhibited by U73122 [3]. The activated PLC generates inositol 1,4,5-trisphosphate (IP₃) which triggers a series of cytosolic Ca²⁺ transients [4,5]. Intracellular repetitive Ca²⁺ oscillations are critical for egg activation and may contribute to the regulation of mouse preimplantational development [6,7]. The Ca²⁺ release occurs predominantly through the IP₃ receptor from intracellular stores [8,9]. Inhibition of the IP₃ receptor by a monoclonal antibody inhibits the Ca²⁺ oscillations and blocks egg activation [4,10]. Acetylcholine, known to activate PLC β , could induce repetitive Ca²⁺ transients of mouse oocytes [11].

The human PLC β_3 gene contains 31 exons and encodes a 1235 amino acid protein [12,13]. The X and Y regions com-

prise 170 and 260 amino acids, respectively. PLC β_3 is the most widely expressed member of the PLC β family [14,15].

The mouse PLC β_3 gene is located on chromosome 19B [16] and shows an overall 92% amino acid identity to the human homolog [17]. PLC β_3 in situ hybridization of rat embryos shows expression in the neural tube at embryonic day (E) 8, and in the thymus as well as lung tissues at E20 [18]. The regulation of PLC β_3 in early embryonic development has not been studied. In an attempt to investigate the biological function of PLC β_3 , we generated mutant mice by gene targeting.

2. Materials and methods

2.1. Construction of the targeting vector

A 1.9 kb 3' human PLC β_3 cDNA fragment was used to screen a 129SV genomic library (Stratagene 946306, USA). The isolated clones were analyzed by digestion with different restriction enzymes (*Xba*I, *Eco*RI, *Eco*RV, *Sac*I, *Bam*HI, *Hind*III). Partial cleavage [19], polymerase chain reaction (PCR) analysis and DNA sequencing were performed to determine the restriction map and genomic organization.

A 4 kb 5' *Sac*I genomic fragment of the PLC β_3 gene was cloned into the *Sac*I site of pBluescript II KS⁻ (Stratagene). A 1.4 kb 3' *Sac*I/*Hind*III genomic fragment of the PLC β_3 gene was blunt-end ligated into a T4 DNA polymerase treated *Xho*I site. Finally, neomycin phosphotransferase expression cassette was blunt-end ligated in sense orientation into the T4 DNA polymerase treated *Not*I site, between the 5' and 3' fragments of PLC β_3 genomic homologues. This resulted in a deletion of a 4 kb genomic DNA fragment containing PLC β_3 exons 11–17, as well as the introduction of an *Eco*RI and an *Eco*RV site.

2.2. Generation of PLC β_3 mutant mice

The embryonic stem (ES) cell line E14.1, derived from the mouse strain 129/Ola, was cultured as described [20]. The targeting vector was linearized with *Pvu*II and electroporated into the ES cells. The neomycin-resistant (G418) ES cell clones were isolated and analyzed by Southern blotting. Two different clones were used for generation of chimeras by injecting the targeted ES cells into C57BL blastocysts and transferred to recipient mice [21]. Both attempts were successful and the targeted ES cells contributed to the germ line of two chimeras.

2.3. Polymerase chain reaction

Routinely, neonates were genotyped by PCR using primers a, b, and c. In selected cases, the genotype was verified by Southern blot analyses, which were consistent with PCR results. All embryos were genotyped by PCR amplification. Embryos or mouse tails were digested with proteinase K. PCR amplifications were performed using three primers (a, b, and c) in a single reaction mixture for 35 cycles (60 s at 94°C, 90 s at 55°C, 120 s at 72°C). The common primer was located in the 3' fragment for homologous recombination (a, 5'-ttgtactcaaacagcctgcgtga-3'). The primer for the wild type allele was located in the deleted exon 17 (b, 5'-agcagctcagccatctaccctaa-

*Corresponding author. Fax: (46) (18) 55 36 01.
E-mail: britt.skogseid@medicin.uu.se

Abbreviations: PLC, phosphatidylinositol-specific phospholipase C; IP₃, inositol 1,4,5-trisphosphate; ES, embryonic stem; PCR, polymerase chain reaction; PGK, phosphoglycerate kinase; Neo, neomycin

3'). The mutant allele primer was in the neomycin resistance gene (c, 5'-cgctatcaggacatagcgttgctca-3') (Fig. 1). In order to further amplify and specify the signals a nested PCR was performed on 2 μ l aliquots of the first PCR products using either primers a' (5'-acacgcctgcgttgagctgcattggc-3') and b' (5'-tgccagctgttgcctcaactcca-3'), or a' together with c' (5'-actgtgctctctagttgccagcat-3'), each located inside the primers a, b and c. PCR products were resolved on 1% agarose gels.

2.4. Culture of preimplantational embryos

Mating was achieved by caging paired heterozygous males and females representing offspring from both chimeras respectively. Embryos were collected on day 2.5 and cultured for 24 or 48 h [22]. Conditions for culturing encompassed M16 medium and a +37°C humidified incubator maintaining a 5% CO₂ atmosphere. Individual embryos were collected and suspended in lysis buffer before PCR amplification.

2.5. Histology and immunohistochemistry

2.5.1. Embryos. Embryos from wild type mouse crossings were collected and fixed overnight in 3% formalin. The fixative was embedded in a drop of melted 2% agar and then cut into 1 mm³ blocks. The agar blocks were dehydrated in ethanol and embedded in paraffin [23]. Mounted sections were stained for the presence of PLC β ₃ using polyclonal antibody against the C-terminal portion of PLC β ₃ (sc-403, Santa Cruz Biotechnology, Santa Cruz, CA, USA) as primary antibody, and biotinylated anti-rabbit as secondary antibody. The immunoreaction was visualized with avidin-horseradish peroxidase and DAB as the chromogen [24]. No positive staining was observed in the absence of the primary antibody.

2.5.2. Tumor tissues. Tumor specimens were fixed in 4% paraformaldehyde and embedded in paraffin. For histological analysis, 5 μ m thick sections were stained with hematoxylin and eosin.

2.6. Western blot analysis

Western blotting was performed according to a modified method [25]. Briefly, 10 μ g of the total protein (quantified by protein assay kit, Pierce, Rockford, IL, USA) was loaded on 4–15% SDS-polyacrylamide gradient gels, transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA, USA) and blocked with 5% non-fat milk for 1 h at room temperature. The membranes were incubated overnight at 4°C with anti-PLC β ₃ (above) diluted 1:1000. After rinsing and washing twice for 10 min with PBS containing 0.1% Tween 20, the filters were incubated for 1 h with a 1/1000 dilution of donkey anti-rabbit IgG conjugated to horseradish peroxidase at room temperature. Subsequently, the filters were washed as above and developed using the ECL Western blotting kit (Amersham, UK). After stripping (according to the ECL Western blotting kit manual) the filters were reprobbed with anti-actin monoclonal antibody (Boehringer Mannheim, Germany). The filters were scanned and target bands were quantified with NIH Image software.

3. Results and discussion

In order to design the targeting construct, genomic DNA clones encompassing the mouse PLC β ₃ gene were isolated from a λ phage library by probing with a human PLC β ₃ cDNA fragment. Eight positive clones were isolated and phage DNA purified. Two overlapping clones spanning the PLC β ₃ coding sequence were restriction mapped by partial cleavage. The genomic structure of mouse PLC β ₃ was determined by DNA sequencing, restriction analysis and genomic PCR. The organization of the mouse gene is similar to that of the human, encompassing 31 exons spanning about 16 kb (Fig. 1A). All analyzed exon-intron boundaries followed the GT-AG intron donor-acceptor splice rule. The Profile Scan Program (<http://isrec-insect.unil.ch/cgi-bin/Callmollusc.pl>) revealed two bipartite nuclear localization signals (aa 469–486 and aa 1100–1117). The amino acid sequence also contains the X (aa 318–469) and Y (aa 590–707) domains [17]. The X region comprises exons 10–13, and the Y region consists of

exons 15–21. The X and Y regions have been reported to be essential for enzymatic activity [26].

The PLC β ₃ gene was disrupted in ES cells by a targeting vector, which resulted in deleting exons 11–17, amino acid sequence 338–681. Two thirds of the X and one third of the Y region as well as one nuclear targeting sequence were removed. The vector contained a neomycin resistance gene flanked by 4.0 kb of genomic DNA upstream of exon 11 as well as 1.4 kb downstream of exon 17 (Fig. 1A). Southern blot analysis showed that five out of 200 neomycin resistant ES cell clones carried a mutant PLC β ₃ allele. Two of these clones (Fig. 1B) were used to generate chimeric mice, and both successfully contributed to the germ line. The genotypes of the mice were determined by PCR or Southern blotting.

No viable homozygous mutant (–/–) pups were identified among 133 offspring from heterozygous (+/–) intercrosses (Table 1). This suggests that inactivation of PLC β ₃ is lethal to the embryo. We were able to produce heterozygous mutant pups by breeding both male and female heterozygotes with wild type mice, indicating that both paternal and maternal sources of PLC β ₃ could sustain embryonic development. To assess the consequences of the PLC β ₃ mutation on embryonic development we analyzed embryos from heterozygote intercrosses at E17.5, E8.5, E3.5, and E2.5 (Table 1). Genotyping was performed by nested PCR amplification (Fig. 1A,C). No –/– embryos were identified at E17.5 nor at E8.5 among 28 embryos. On embryonic day 3.5, 57 embryos were genotyped and only one, which showed normal morphology for date, was homozygous for the mutant allele. On E2.5 however, 14 of 99 embryos were identified as homozygous mutants. Ten of these homozygotes showed abnormalities characterized by poor embryonic organization and a substantial reduction of cell numbers compared to wild type and heterozygous littermates: mean number of cells 4.0 ± 0.6 (S.E.M.) vs. 7.5 ± 0.1 (S.E.M.) ($P < 0.0001$) (Table 1). Sixty-one of the 99 E2.5 morulas showed a heterozygous genotype and the remaining 24 represented wild types. Only two of the wild types and one heterozygote showed abnormal morphology at E2.5. Additionally, we collected day 2.5 embryos from heterozygous matings for culturing. Forty-two embryos were cultured for 24 h and both wild type and heterozygotes developed blastocyst cavities. Forty-five embryos were cultured for 48 h, the wild type and heterozygotes formed late expanded blastocysts. The 11 mutants, however, failed to form blastocyst cavities and four appeared distorted at 48 h (Fig. 2). Homozygous mutants generated from the two independently targeted ES cell clones showed identical phenotypes. These results demon-

Table 1
Genotypic and phenotypic analysis of neonates and embryos from PLC β ₃ heterozygous intercrosses

Stage	Total number	Genotype ^a		
		+/+	+/-	-/-
Neonate	133	40 (0)	93 (1)	0
E17.5	5	2 (0)	3 (0)	0
E8.5	23	8 (0)	15 (1)	0
E3.5	57	16 (1)	40 (2)	1
E2.5	99	24 (1)	61 (2)	14 (10)

The embryos were collected on embryonic days 17.5, 8.5, 3.5, and 2.5. Abnormal phenotypes encompassed poor embryonic organization and reduced cell numbers in comparison with control littermates.

^aNumber of abnormal individuals in parentheses.




Fig. 2. Morphology of embryos. A: E2.5 embryos. The wild type and heterozygous mutant embryos showed the 8-cell stage. The mutant remained at the 4-cell stage. B: E2.5 embryos cultured for 24 h. Both wild type and heterozygote developed blastocoele cavities, but the mutant failed to do so. C: E2.5 embryos cultured for 48 h. Wild type and heterozygotes had developed up to the expanded blastocysts. The mutant appeared distorted and no blastocoele cavity was formed.

tumor although in less severe stages of the disease. A larger number of mice need to be investigated in order to fully understand the nature of these tumors. Heterozygotes (mean age 16 months) descending from our second chimera have not developed lymphomas, suggesting that the observed tumors are not specifically related to the mutant PLCβ₃ allele.

The data presented here show that PLCβ₃ deficient embryos suffer from a developmental arrest at E2.5 indicating that PLCβ₃ is essential for cellular proliferation at early embryonic stages. The mutant phenotype was most likely caused by disruption of the PLCβ₃ gene rather than alterations elsewhere in the ES cell genome since the offspring of the second chimera, derived from independently targeted ES cells, showed the same early embryonic lethality and presented no signs of lymphomas. Only 14% of E2.5 embryos presented a homozygous mutant genotype, implying that some of the -/- mutants

disappeared before the first morphological event of differentiation. Alternatively, this unexpectedly low frequency could constitute an underestimation due to PCR contamination. Unfortunately, we had difficulties obtaining consistent results from genotyping E1.5 embryos, again, mainly due to the limited DNA templates. High expression of PLCβ₃ was found in wild type unfertilized eggs, 3-cell stage embryos and egg cylinders. Substantial expression in eggs and morulae possibly reflects that PLCβ₃ function is essential for cleavage of zygotes and early embryos. It seems likely that maternal sources of PLCβ₃ are inadequate in sustaining embryos beyond the 4-cell stage since 10 out of 14 homozygous mutants encompassed four cells or fewer. Several laboratories have found that inositol triphosphate-induced Ca²⁺ oscillations are associated with developmental events, including egg activation and fertilization [8,27,28]. Han et al. [29] observed that the blas-




Fig. 3. Immunohistochemical detection of the PLCβ₃ protein in mouse embryos. A: Unfertilized egg. B: 3-cell embryo. C: Egg cylinder.




Fig. 4. PLC β_3 expression in lung tissue of wild type and heterozygous mice analyzed by Western blot. The top panel shows an immunoblot with PLC β_3 antibody and the lower with monoclonal actin. Lanes 1–4 contain extracts from wild type tissue and lanes 5–8 from heterozygous.

tomere stopped dividing after inhibition of PLC suggesting that intracellular calcium release is mediated through a PLC-dependent pathway. Becchetti and Whitaker reported that lithium, an inhibitor of the phosphoinositide pathway, blocked the cell cycle in sea urchin embryos at the 4-cell stage. The block was reversed by IP $_3$ indicating that phosphoinositide signaling is involved in the cell cycle of the early embryo [30]. Both the tyrosine kinase and G-protein coupled pathways are believed to be involved in egg activation and preimplantational development [31]. Deficiency studies of PLC β_1 , β_4 and PLC γ_1 in mice have recently been performed [32–34]. Lethality before birth was not seen in PLC β_1 or PLC β_4 null mice. Instead, impaired visual processing abilities and ataxia were noted in PLC β_4 null mice [32,33]. The PLC β_1 mutant pups developed epilepsy and showed failure to thrive [33]. Homozygous disruption of PLC γ_1 resulted in embryonic lethality at E9 [34].

In conclusion, targeted disruption of PLC β_3 was performed in mice. Homozygous deletion of the PLC β_3 gene leads to preimplantational embryonic lethality, hence, PLC β_3 cannot be compensated by other isozymes or signaling pathways.

Acknowledgements: This work was supported by the Swedish Cancer Society, Lions Foundation for Cancer Research, Swedish Medical Council and Torsten and Ragnar Söderbergs foundation. We would like to thank Prof. Christer Sundström for classification of the lymphoma lesions, and Prof. Ove Nilsson for providing embryonic sections.

References

- [1] Miyazaki, S., Shirakawa, H., Nakada, K. and Honda, Y. (1993) *Dev. Biol.* 158, 62–78.
- [2] Dupont, G., McGuinness, O.M., Johnson, M.H., Berridge, M.J. and Borgese, F. (1996) *Biochem. J.* 316, 583–591.
- [3] Stachecki, J.J. and Armant, D.R. (1996) *Biol. Reprod.* 55, 1292–1298.
- [4] Miyazaki, S., Yuzaki, M., Nakada, K., Shirakawa, H., Nakanishi, S., Nakade, S. and Mikoshiba, K. (1992) *Science* 257, 251–255.
- [5] Peres, A. (1990) *FEBS Lett.* 275, 213–216.
- [6] Stachecki, J.J. and Armant, D.R. (1996) *Development* 122, 2485–2496.
- [7] Vitullo, A.D. and Ozil, J.P. (1992) *Dev. Biol.* 151, 128–136.
- [8] Sato, Y., Miyazaki, S., Shikano, T., Mitsuhashi, N., Takeuchi, H., Mikoshiba, K. and Kuwabara, Y. (1998) *Biol. Reprod.* 58, 867–873.
- [9] Rickords, L.F. and White, K.L. (1993) *J. Exp. Zool.* 265, 178–184.
- [10] Xu, Z., Kopf, G.S. and Schultz, R.M. (1994) *Development* 120, 1851–1859.
- [11] Cheek, T.R., McGuinness, O.M., Vincent, C., Moreton, R.B., Berridge, M.J. and Johnson, M.H. (1993) *Development* 119, 179–189.
- [12] Mazuruk, K., Schoen, T.J., Chader, G.J. and Rodriguez, I.R. (1995) *Biochem. Biophys. Res. Commun.* 212, 190–195.
- [13] Lagercrantz, J., Carson, E., Larsson, C., Nordenskjold, M. and Weber, G. (1996) *Genomics* 31, 380–384.
- [14] Smrcka, A.V. and Sternweis, P.C. (1993) *J. Biol. Chem.* 268, 9667–9674.
- [15] Weber, G., Friedman, E., Grimmond, S., Hayward, N.K., Phe-lan, C., Skogseid, B., Gobl, A., Zedenius, J., Sandelin, K. and Teh, B.T. et al. (1994) *Hum. Mol. Genet.* 3, 1775–1781.
- [16] Gobl, A.E., Chowdhary, B.P., Shu, W., Eriksson, L., Larsson, C., Weber, G., Oberg, K. and Skogseid, B. (1995) *Cytogenet. Cell Genet.* 71, 257–259.
- [17] Wang, S., Zhou, Y., Lukinius, A., Oberg, K., Skogseid, B. and Gobl, A. (1998) *Biochim. Biophys. Acta* 1393, 173–178.
- [18] Lagercrantz, J., Piehl, F., Nordenskjold, M., Larsson, C. and Weber, G. (1995) *NeuroReport* 6, 2542–2544.
- [19] Bloch, K.D. (1994) in: *Current Protocols in Molecular Biology* (Ausubel, F.M., Brent, P., Kingston, R.E. et al., Eds.), pp. 3.1.3–3.3.2, John Wiley and Sons, New York.
- [20] Kuhn, R., Rajewsky, K. and Muller, W. (1991) *Science* 254, 707–710.
- [21] Leveen, P., Pekny, M., Gebre-Medhin, S., Swolin, B., Larsson, E. and Betsholtz, C. (1994) *Genes Dev.* 8, 1875–1887.
- [22] Hogan, B., Beddington, R., Costantini, F. and Lacy, E. (1994) in: *Manipulating the Mouse Embryo* (Hogan, B., Beddington, R., Costantini, F. et al., Eds.), pp. 385–413, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
- [23] Kattstrom, P.O., Bjerneroth, G., Nilsson, B.O., Holmdahl, R. and Larsson, E. (1989) *Cell. Differ. Dev.* 28, 47–54.
- [24] Funai, K., Papanicolaou, V., Juhlin, C., Rastad, J., Akerstrom, G., Heldin, C.H. and Oberg, K. (1990) *Cancer Res.* 50, 748–753.
- [25] Zhou, Y., Wang, S., Gobl, A. and Oberg, K. (1998) *Eur. J. Cancer* (in press).
- [26] Noh, D.Y., Shin, S.H. and Rhee, S.G. (1995) *Biochim. Biophys. Acta* 1242, 99–113.
- [27] Turner, P.R., Sheetz, M.P. and Jaffe, L.A. (1984) *Nature* 310, 414–415.
- [28] Kume, S., Muto, A., Okano, H. and Mikoshiba, K. (1997) *Mech. Dev.* 66, 157–168.
- [29] Han, J.K., Fukami, K. and Nuccitelli, R. (1992) *J. Cell. Biol.* 116, 147–156.
- [30] Becchetti, A. and Whitaker, M. (1997) *Development* 124, 1099–1107.
- [31] Shilling, F.M., Carroll, D.J., Muslin, A.J., Escobedo, J.A., Williams, L.T. and Jaffe, L.A. (1994) *Dev. Biol.* 162, 590–599.
- [32] Jiang, H., Lyubarsky, A., Dodd, R., Vardi, N., Pugh, E., Baylor, D., Simon, M.I. and Wu, D. (1996) *Proc. Natl. Acad. Sci. USA* 93, 14598–14601.
- [33] Kim, D., Jun, K.S., Lee, S.B., Kang, N.G., Min, D.S., Kim, Y.H., Ryu, S.H., Suh, P.G. and Shin, H.S. (1997) *Nature* 389, 290–293.
- [34] Ji, Q.S., Winnier, G.E., Niswender, K.D., Horstman, D., Wisdom, R., Magnuson, M.A. and Carpenter, G. (1997) *Proc. Natl. Acad. Sci. USA* 94, 2999–3003.